Jean-mathieu Beauregard
Laval, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?
Journal: European urology focus
Published: May 29, 2026
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: February 17, 2026
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: May 22, 2025
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 16, 2024
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Journal: Frontiers in oncology
Published: August 20, 2024
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 31, 2024
Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical Care.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 23, 2024
Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 13, 2023
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 02, 2023
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 12, 2023
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 23, 2022
Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
Journal: Clinical nuclear medicine
Published: October 14, 2022
Last Updated: 09/26/2026